Nature Communications · 2023 · 59 citations · 57 references
Life SciencesImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyAdaptive Immune ResponsesAntigen DesignB-cell ResponsesCell-mediated ImmunityVaccine Antigen DesignViral VaccinesAdaptive Immune Responses To Viral InfectionCellular Immune Response To VirusesEpitope-focused VaccinesMulti-epitope VaccinesPolyepitope Vaccine ConstructsT-cell Epitope VaccinesVaccine Adjuvant DevelopmentVaccine Adjuvant Therapy
Abstract The recent emergence of a causal link between Epstein-Barr virus (EBV) and multiple sclerosis has generated considerable interest in the development of an effective vaccine against EBV. Here we describe a vaccine formulation based on a lymph node targeting Amphiphile vaccine adjuvant, Amphiphile-CpG, admixed with EBV gp350 glycoprotein and an engineered EBV polyepitope protein that includes 20 CD8 + T cell epitopes from EBV latent and lytic antigens. Potent gp350-specific IgG responses are induced in mice with titers >100,000 in Amphiphile-CpG vaccinated mice. Immunization including Amphiphile-CpG also induces high frequencies of polyfunctional gp350-specific CD4 + T cells and EBV-specific CD8 + T cells that are 2-fold greater than soluble CpG and are maintained for >7 months post immunization. This combination of broad humoral and cellular immunity against multiple viral determinants is likely to provide better protection against primary infection and control of latently infected B cells leading to protection against the development of EBV-associated diseases.
57
The Immune Epitope Database (IEDB): 2018 update
Randi Vita, Swapnil Mahajan, James A. Overton et al. · Nucleic Acids Research · 2018 · 2.3K citations · Full text
Predicting population coverage of T-cell epitope-based diagnostics and vaccines
Huynh‐Hoa Bui, John Sidney, Kenny Dinh et al. · BMC Bioinformatics · 2006 · 987 citations · Full text
Life Sciences, Genetics, Immunology +17